Suez Canal University

scu.edu.eg

Total trials

145

Active

40

Phase 3

6

Total enrollment

309,030

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Intranasal dexmedetomidine1
Intranasal normal saline1
non surgical with PUFA1
Calcium Hydroxide Intracanal medication1
Calcium silicate based intracanal medication1
Pectin1
Normal Saline5
ondansetron lingual film1
vit D mixed with xenograft1
only xenograft without vit D1
Corticosteroid1
Mineral trioxide aggregate1
Melatonin1
Melatonin gel1
Ondansetron 8mg1

Next readouts

  • 2024-06
  • 2024-09-20
  • 2025-06-15
  • 2025-08-07
  • 2026-03-10
  • 2026-04
  • 2026-07-01
  • 2026-07-20
  • 2026-10-10

Top conditions

  • Postoperative Pain6
  • Carcinoid Tumor3
  • Dental Caries in Children3
  • Implant Therapy3
  • Dental Fluorosis2
  • Knee Osteoarthritis2
  • Mandibular Fracture Treatment2
  • Cataract2

Frequently asked questions about Suez Canal University

How many clinical trials does Suez Canal University have on ClinicalTrials.gov?
Suez Canal University is listed as the lead sponsor on 145 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
How many of Suez Canal University's trials are in Phase 3?
6 of Suez Canal University's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does Suez Canal University focus on?
Suez Canal University's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Carcinoid Tumor, Dental Caries in Children, Implant Therapy, Dental Fluorosis.
When are Suez Canal University's next clinical trial readouts?
Suez Canal University has 9 upcoming primary-completion readouts tracked here; the soonest is “Effect of Apical Patency and Local Corticosteroid on Pain and Neuropeptides Release in Patients With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial”, expected around 2024-06.